NasdaqGS:ACADBiotechs
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback
ACADIA Pharmaceuticals (ACAD) is back in focus after first quarter 2026 results showed 10% year over year revenue growth to US$268.1 million, alongside weaker earnings, higher expenses, and a setback for trofinetide in Europe.
See our latest analysis for ACADIA Pharmaceuticals.
The mixed Q1 2026 update, together with the negative EU opinion on trofinetide and leadership changes in research and development, appears to be feeding into a share price that has struggled year to date despite a...